Cor.At® mouse stem cel-derived cardiomyocytes can be transiently transfected with relevant nucleic acids to study i.e. protein trafficking or ion channel composition. Highly efficient and reproducible transfection of Cor.At® cardiomyocytes can be achieved using the Nucleofector technology by Lonza (former Amaxa GmbH), resulting in a transfection efficiency of 61% with 86% survival rate. The morphology and characteristics of the Cor.At® cardiomyocytes are not affected by the transfection process, as indicated by spontaneous beating in less than 12h after transfection.
If lower transfection efficiencies are sufficient for the experimental set-up, it is also possible to use a conventional electroporator. Approximated transfection efficiency of 10-20% can be achieved when using a Multiporator® and a hypoosmolar buffer (Eppendorf).
Cor.At® cardiomyocytes can efficiently be used for target validation studies using siRNA technolgies. The transfection with siRNA can be used to down-regulate target genes (Fig. 1).
